Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: Synthesis and pharmacological evaluation

European Journal of Medicinal Chemistry

Volumn 45, Issue 11, 2010, Pages 5113-5119

  Alam, Ozair ^a   Khan, Suroor A ^a   Siddiqui, Nadeem ^a   Ahsan, Waquar ^a   Verma, Suraj P ^a   Gilani, Sadaf J ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Antihypertensive activity; Dihydropyridine; Dihydropyrimidine; DOCA salt

Indexed keywords

5 (4 BROMOPHENYL) 2 (2 CHLOROBENZYLSULFANYL) 4 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 (2 CHLOROBENZYLSULFANYL) 4 (4 METHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 (2 FLUOROBENZYLSULFANYL) 4 (4 METHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 (3 CHLOROBENZYLSULFANYL) 4 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 (3 CHLOROBENZYLSULFANYL) 4 (4 METHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 (4 CHLOROBENZYLSULFANYL) 4 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 (4 CHLOROBENZYLSULFANYL) 4 (4 METHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 (4 FLUOROBENZYLSULFANYL) 4 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 BENZYLSULFANYL 4 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 BROMOPHENYL) 2 BENZYLSULFANYL 4 (4 METHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (2 CHLOROBENZYLSULFANYL) 4 (3,4 DIMETHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (2 CHLOROBENZYLSULFANYL) 4 (4 NITROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (3 CHLOROBENZYLSULFANYL) 4 (3,4 DIMETHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (3 CHLOROBENZYLSULFANYL) 4 (4 NITROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (4 CHLOROBENZYLSULFANYL) 4 (3,4 DIMETHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (4 CHLOROBENZYLSULFANYL) 4 (4 NITROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (4 FLUOROBENZYLSULFANYL) 4 (3,4 DIMETHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 (4 FLUOROBENZYLSULFANYL) 4 (4 NITROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 BENZYLSULFANYL 4 (3,4 DIMETHOXYPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 FLUOROPHENYL) 2 BENZYLSULFANYL 4 (4 NITROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 NITROPHENYL) 2 (2 CHLOROBENZYLSULFANYL) 4 (4 BROMOPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 NITROPHENYL) 2 (3 CHLOROBENZYLSULFANYL) 4 (4 BROMOPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 NITROPHENYL) 2 (4 CHLOROBENZYLSULFANYL) 4 (3 NITROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 NITROPHENYL) 2 (4 CHLOROBENZYLSULFANYL) 4 (4 BROMOPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 NITROPHENYL) 2 (4 FLUOROBENZYLSULFANYL) 4 (4 BROMOPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 NITROPHENYL) 2 (BENZYLSULFANYL) 4 (3 NITROPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; 5 (4 NITROPHENYL) 2 (BENZYLSULFANYL) 4 (4 BROMOPHENYL) 6 METHYL 1,4 DIHYDRO 5 PYRIMIDINECARBOXAMIDE; AMIDE; NIFEDIPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DESOXYCORTICOSTERONE; DRUG EVALUATION, PRECLINICAL; HYPERTENSION; MAGNETIC RESONANCE SPECTROSCOPY; PYRIMIDINES; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 77957848203     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.08.022     Document Type: Article

References (13)

1. C.J.L. Murray, and A.D. Lopez The Global Burden of Disease 1996 Harvard University Press Cambridge, Mass pp. 1-98
2. R.A. Janis, P.J. Silver, and D.J. Triggle Adv. Drug Res. 16 1987 309 591
3. C.O. Kappe Tetrahedron 49 1993 6937 6963
4. G.C. Rovnyak, K.S. Atwal, A. Hedberg, S.D. Kimball, S. Moreland, J.Z. Gougoutas, B.C. O'Reilly, J. Schwartz, and M.F. Malley J. Med. Chem. 35 1992 3254 3263
5. K.S. Atwal, B.N. Swanson, S.E. Unger, D.M. Floyd, S. Moreland, A. Hedberg, and B.C. O'Reilly J. Med. Chem. 34 1991 806 811
6. S.S. Bahekar, and B.D. Shinde Acta Pharm. 53 2003 223 229
7. G.C. Rovnyak, C.O. Kimball, B. Beyer, G. Cucinotta, J.D. Di-Marco, J. Gougoutas, A. Hedberg, M. Malley, J.P. McCarthy, R. Zhang, and S. Moreland J. Med. Chem. 38 1995 119 129
8. R.T. Passaglia, F.L. David, and Z.B. Fortes Br. J. Pharmacol. 130 2000 1092 1098
9. C. Johns, I. Gravras, D.E. Handy, and A. Salomao Hypertension 28 1996 1064 1069
10. G.H. Vogel Drug Discovery and Evaluation 2002 Springer-Verlag Berlin Heidelberg Publications New York pp. 175
11. K.Y. Shinozuka, and K.K. Nakamura Biol. Pharm. Bull. 29 2006 1756 1763
12. C.S. Bockman, W.B. Jeffries, W.A. Pettinger, and P.W. Abel Am. J. Physiol. 262 1992 1752 1758
13. R.P. Lee, D. Wang, and H.I. Chen J. Biomed. Sci. 9 2002 424 429